*Some Market data delayed by 15 mins.

Cellectis S.A. American Depositary Shares

Symbol: CLLS (NASDAQ)
3.24 ▲ (6.20%) 0.189

Company Description:
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Key Stats
  • Today's Open: $3.27
  • Today's High: $3.318
  • Today's Low: $3.017
  • Today's Volume: 59.18K
  • Yesterday Close: $3.05
  • Yesterday High: $3.18
  • Yesterday Low: $2.9
  • Yesterday Volume: 197.19K
  • Last Min Volume: 166
  • Last Min High: $3.22
  • Last Min Low: $3.216
  • Last Min VWAP: $3.21881
Company Profile
  • Name: Cellectis S.A. American Depositary Shares
  • Website: https://www.cellectis.com
  • Listed Date: 2015-03-25
  • Location: ,
  • Market Status: Active
  • CIK Number: 0001627281
  • SIC Code:
  • SIC description:
  • Market Cap: $305.99M
  • Round Lot: 100
  • Outstanding Shares: 100.33M
  • Asset Type: ADRC
RECENT FILINGS FOR CLLS
Filing Date Filing Type Format
2025-08-04 6-K View
2025-08-04 6-K View
2025-07-28 6-K View
2025-07-11 EFFECT View
2025-07-09 CORRESP View
2025-07-07 UPLOAD View
2025-07-02 F-3 View
2025-06-26 6-K View
2025-06-26 6-K View
2025-05-21 6-K View
2025-05-21 6-K View
2025-05-12 6-K View
2025-05-12 6-K View
2025-05-06 6-K View
2025-04-28 6-K View
2025-03-31 6-K View
2025-03-14 20-F/A View
2025-03-14 20-F View
2025-03-07 6-K View
2025-02-24 6-K View
Latest News on CLLS

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.